Pharmacy and drug forms

503B bulk drug substances list

Where a compounded drug parts company with an FDA-approved one, where 503A parts company with 503B, and which accreditation programs tell them apart.

Definition

The FDA list of active ingredients a 503B outsourcing facility may compound from when there is no approved drug shortage. On 30 April 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from it — which, if finalized, closes the remaining lawful route for compounding GLP-1s at scale.

Which GLP-1s can be compounded

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under Pharmacy and drug forms

Where the evidence lives